Peyronie's Disease Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceAntioxidant that may reduce oxidative stress contributing to plaque formation
Classic antioxidant therapy for PD; may reduce plaque progression
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsShown to reduce plaque size and curvature in studies; supports tissue healing
Supporting Studies (1)
Anti-inflammatory effects may help reduce fibrosis progression
Supporting Studies (1)
May have anti-fibrotic effects; historically used for fibrotic conditions
Supporting Studies (1)
May support tissue remodeling and healing
Supporting Studies (1)
Supports wound healing and tissue repair
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Peyronie's disease (PD) is a condition where scar tissue (plaque) forms in the penis, causing curvature, pain, and erectile dysfunction. It typically begins after minor trauma to the penis during sex. The scar tissue forms as part of abnormal wound healing in genetically susceptible individuals. PD has two phases: the acute/active phase (pain, plaque forming, curvature worsening) lasting 6-18 months, and the stable/chronic phase (pain resolves, plaque and curvature stabilize). About 10% of men are affected.
CRITICAL: Peyronie's disease treatment depends on the phase and severity. In the acute phase, conservative management (supplements, traction devices) may help limit progression. In the stable phase with significant deformity, medical and surgical options include: intralesional injections (collagenase/Xiaflex, verapamil), traction therapy, and surgery (plication, grafting, implants). See a urologist who specializes in PD. Supplements may provide modest benefit but won't reverse established plaques. Evidence for most supplements is limited. Sexual counseling and psychological support are important components of care.
* Coenzyme Q10 has shown the most promise in clinical trials, with one study showing reduced curvature progression and plaque size compared to placebo.
* Vitamin E is the most traditionally used supplement for PD, though evidence is actually limited. It's thought to work through antioxidant effects. Often combined with other treatments.
* Acetyl-L-Carnitine has shown benefit in some studies, with effects on pain, curvature, and plaque size comparable to or better than vitamin E.
* Omega-3 Fatty Acids may help through anti-inflammatory and anti-fibrotic effects.
* PABA (Potassium Para-aminobenzoate) has been used historically for fibrotic conditions. High doses are needed, which can cause GI side effects.
* Collagen and Zinc support tissue healing in general.
Expected timeline: PD natural history: acute phase 6-18 months, then stabilizes. Supplements are most likely to help during the acute phase when plaque is still forming. Allow 3-6 months to assess benefit. Surgery is reserved for stable disease with significant deformity.
Clinical Perspective
Peyronie's disease: acquired fibrosis of tunica albuginea. Prevalence: ~5-10% of men; increases with age. Pathophysiology: trauma → inflammation → abnormal wound healing → fibrosis in genetically susceptible. Risk factors: diabetes, Dupuytren's contracture, trauma, hypertension, ED. Phases: acute (pain, plaque developing, curvature changing) 6-18 months; chronic/stable (pain resolves, plaque stabilizes). Presentation: penile curvature, pain (especially with erection), palpable plaque, ED (50%), psychological distress.
CRITICAL: Evaluation: history, physical exam (plaque location, curvature degree, stretched penile length), duplex ultrasound with induced erection in some cases. Treatment by phase: Acute - conservative (oral agents, traction); Stable with significant deformity - intralesional (collagenase clostridium histolyticum, verapamil, interferon) or surgery. Collagenase (Xiaflex): FDA-approved for curvature >30° with palpable plaque. Surgery: reserved for stable disease (>12 months), significant curvature (>30°), or ED requiring prosthesis. Psychological support important.
* CoQ10 (B-grade): Antioxidant; mitochondrial support. Clinical trial: reduced progression (PMID: 21054003). Review: antioxidant therapy (PMID: 26475365). 200-300mg daily.
* Vitamin E (C-grade): Classic therapy; limited evidence. Review: historical use (PMID: 12394730). 400-800 IU daily. Often combined with other agents.
* Acetyl-L-Carnitine (B-grade): Tissue healing; antifibrotic. Clinical trial: comparable to tamoxifen (PMID: 11275384). 1-2g daily.
* Omega-3 Fatty Acids (C-grade): Anti-inflammatory. Review: anti-inflammatory agents (PMID: 23676497). 2-3g EPA+DHA daily.
* PABA (C-grade): Anti-fibrotic; historical use. Review: mechanisms (PMID: 16483233). 12g daily divided. GI side effects limit use.
* Collagen (D-grade): Tissue support. Review: healing (PMID: 28177710). 5-10g daily.
* Zinc (D-grade): Wound healing support. Review: healing (PMID: 9449242). 25-50mg daily.
Biomarker targets: Pain resolution, curvature stability/improvement (measured by goniometer or photos), plaque size, erectile function (IIEF).
Protocol notes: Traction therapy: evidence supports; devices like RestoreX, Andropenis; 30 min - 3 hours daily for months. Can be combined with other treatments. Collagenase (Xiaflex): most effective medical therapy; 4 treatment cycles; requires proper patient selection and injection technique. Intralesional verapamil: alternative if collagenase unavailable/contraindicated. Pentoxifylline: 400mg TID; some evidence; anti-fibrotic. Surgical options: plication (Nesbit, dots) for mild-moderate curvature with good length/erections; grafting for severe curvature; penile prosthesis if ED unresponsive to other treatment. Expectations: curvature may stabilize but rarely completely resolves; supplements may limit progression; surgery straightens but may shorten. Psychological impact: significant; depression and relationship issues common; consider counseling. ED concurrent: treat with PDE5 inhibitors if responsive. Natural history: 12% spontaneous improvement, 48% stable, 40% worsen without treatment.